Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Abstract 1574: KRAS genotyping by digital PCR combining melting curve analysis

View through CrossRef
Abstract Background ctDNA is a remarkable liquid biopsy for cancer diagnosis. Highly sensitive quantification method is required to measure a tiny amount of ctDNA. Digital PCR has been developed as a method that can quantify nucleic acids more sensitively than real-time PCR does. However, the digital PCR has large fluctuation in the fluorescence intensity of the droplets or chambers resulting in lower accuracy. Main cause is probably due to the insufficient PCR in the small partitions. In this study, we have proposed a new measurement method combined a digital PCR with melting curve analysis using molecular beacons to solve above mentioned problems, and applied it to KRAS genotyping. Methods Molecular beacons, which have hydrophobic moiety in the stem, were designed for detecting KRAS mutation. The digital PCR with combination of asymmetric PCR was performed using the molecular beacons in the droplets. After the PCR, the fluorescence of the droplets was observed with a microscope while changing the temperature. A melting curve was prepared from the change in fluorescence intensity of the droplet, and the melting temperature (Tm) was calculated from the differential melting curve. Results The melting curve analysis for the KRAS mutation was performed in the droplets where the asymmetric PCR was performed using molecular beacons with hydrophobic stem, which improved signal-to-noise ratio of melting curves. The use of molecular beacons with hydrophobic stem can keep a background fluorescence at a constant value even at high temperature. The change in fluorescence intensity of PCR solution using molecular beacons with hydrophobic stem during the measurement was one-tenth of that using molecular beacon without hydrophobic stem. The asymmetric PCR enabled us to increase the amount of the PCR products hybridized with molecular beacons, resulting in the increase in the fluorescence intensity. The KRAS genotyping of wild-type (WT) and G12D mutant was conducted by the melting curve analysis with a combination of the asymmetric PCR with molecular beacons. The results showed that the peaks of the distributions of the Tm values of DNA in the droplets were 77.9°C for WT and 74.0°C for G12D mutant, which indicates that the WT and the mutant could be successfully discriminated by the proposed method. Conclusion We have proposed a new measurement method combining digital PCR with asymmetric PCR using molecular beacons and melting curve analysis. The genotyping of KRAS mutation was successfully performed by the proposed method. We are planning to prove the concept of this method for the clinical specimens in the future. Citation Format: Junko Tanaka, Yuzuru Shimazaki, Tatsuo Nakagawa, Akiko Shiratori, Masao Kamahori, Takahide Yokoi, Kunio Harada, Yoshinobu Kohara. KRAS genotyping by digital PCR combining melting curve analysis [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 1574.
Title: Abstract 1574: KRAS genotyping by digital PCR combining melting curve analysis
Description:
Abstract Background ctDNA is a remarkable liquid biopsy for cancer diagnosis.
Highly sensitive quantification method is required to measure a tiny amount of ctDNA.
Digital PCR has been developed as a method that can quantify nucleic acids more sensitively than real-time PCR does.
However, the digital PCR has large fluctuation in the fluorescence intensity of the droplets or chambers resulting in lower accuracy.
Main cause is probably due to the insufficient PCR in the small partitions.
In this study, we have proposed a new measurement method combined a digital PCR with melting curve analysis using molecular beacons to solve above mentioned problems, and applied it to KRAS genotyping.
Methods Molecular beacons, which have hydrophobic moiety in the stem, were designed for detecting KRAS mutation.
The digital PCR with combination of asymmetric PCR was performed using the molecular beacons in the droplets.
After the PCR, the fluorescence of the droplets was observed with a microscope while changing the temperature.
A melting curve was prepared from the change in fluorescence intensity of the droplet, and the melting temperature (Tm) was calculated from the differential melting curve.
Results The melting curve analysis for the KRAS mutation was performed in the droplets where the asymmetric PCR was performed using molecular beacons with hydrophobic stem, which improved signal-to-noise ratio of melting curves.
The use of molecular beacons with hydrophobic stem can keep a background fluorescence at a constant value even at high temperature.
The change in fluorescence intensity of PCR solution using molecular beacons with hydrophobic stem during the measurement was one-tenth of that using molecular beacon without hydrophobic stem.
The asymmetric PCR enabled us to increase the amount of the PCR products hybridized with molecular beacons, resulting in the increase in the fluorescence intensity.
The KRAS genotyping of wild-type (WT) and G12D mutant was conducted by the melting curve analysis with a combination of the asymmetric PCR with molecular beacons.
The results showed that the peaks of the distributions of the Tm values of DNA in the droplets were 77.
9°C for WT and 74.
0°C for G12D mutant, which indicates that the WT and the mutant could be successfully discriminated by the proposed method.
Conclusion We have proposed a new measurement method combining digital PCR with asymmetric PCR using molecular beacons and melting curve analysis.
The genotyping of KRAS mutation was successfully performed by the proposed method.
We are planning to prove the concept of this method for the clinical specimens in the future.
Citation Format: Junko Tanaka, Yuzuru Shimazaki, Tatsuo Nakagawa, Akiko Shiratori, Masao Kamahori, Takahide Yokoi, Kunio Harada, Yoshinobu Kohara.
KRAS genotyping by digital PCR combining melting curve analysis [abstract].
In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL.
Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 1574.

Related Results

Kras Plays An Important Role In Generating Differentiated Blood Cells
Kras Plays An Important Role In Generating Differentiated Blood Cells
Abstract Background Kras is a small GTPase essential for mouse embryonic development. Although Kras-/- fetal liver cells reconst...
Abstract IA07: Molecular characterization of acquired resistance to KRASG12C-EGFR inhibition in colorectal cancer
Abstract IA07: Molecular characterization of acquired resistance to KRASG12C-EGFR inhibition in colorectal cancer
Abstract Until recently, efforts to pharmacologically target KRAS have been unsuccessful due to its small binding pocket, high affinity for GTP, and redundant mechan...
Interleukin-1β as target to induce synthetic lethality in KRAS mutant biliary tract cancer
Interleukin-1β as target to induce synthetic lethality in KRAS mutant biliary tract cancer
Background/Aims: Biliary tract cancer (BTC) frequently harbors KRAS mutations, which are associated with resistance to traditional treatment and a poor prognosis. Synthetic lethali...
Escaping KRAS: Gaining Autonomy and Resistance to KRAS Inhibition in KRAS Mutant Cancers
Escaping KRAS: Gaining Autonomy and Resistance to KRAS Inhibition in KRAS Mutant Cancers
Activating mutations in KRAS are present in 25% of human cancers. When mutated, the KRAS protein becomes constitutively active, stimulating various effector pathways and leading to...
Clinical outcome in patients with metastatic colorectal cancer harboring KRAS p.G13D mutation treated with cetuximab.
Clinical outcome in patients with metastatic colorectal cancer harboring KRAS p.G13D mutation treated with cetuximab.
448 Background: Metastatic colorectal cancer patients with KRAS codon 12 or 13 mutated tumors are presently excluded from treatment with cetuximab (Cmab). On the other hand, a few...
Mutasi Gen KRAS Ekson 2 Kodon 12 dan 13 Pada Pasien Kanker Kolorektal di RSUP Prof. Dr. I.G.N.G. Ngoerah Tahun 2018-2019
Mutasi Gen KRAS Ekson 2 Kodon 12 dan 13 Pada Pasien Kanker Kolorektal di RSUP Prof. Dr. I.G.N.G. Ngoerah Tahun 2018-2019
Background: Colorectal cancer is commonly found to be regulated by the KRAS gene mutation. Studies reporting the occurrence of mutations in the KRAS gene in Indonesia are still lim...

Back to Top